PRSS22

Across TCGA pan-cancer cohorts, PRSS22 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRSS22 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PRSS22 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRSS22 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where PRSS22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.287	0.900	.006	24	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.761	.011	20	view →
LUAD	OS	Tertile	III,IV	0.314	0.931	.009	15	view →
HNSC	OS	Tertile	All	1.000	0.418	.044	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRSS22–PDAC (DFS)

Open the PDAC breakdown →